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Introduction: Thalassemia patient lifespan nowadays has been increased 
significantly compared previously due to the advancement of medical treatment 
and better healthcare system. As a result, more transfusion-related complication 
has been seen, and one of the rising trends was the thromboembolic complication. 
Studies had shown that ultrasound measurement of carotid artery intima media 
thickness (CIMT) can be used as a surrogate marker for future cardiovascular 
event and is recommended to be done in t halassemia patient as early diagnostic 
tool and for vascular risk stratification.  
 
Objectives: The aim of this study were to compare the CIMT value between 
thalassemia patients and normal population and to find any correlation between 
thalassemia CIMT measurement with patient’s age, disease duration, number of 
blood transfusion and serum ferritin levels.   
Methods: All thalassemia patient attending treatment and follow-up at HUSM 
who fulfilled the inclusion criteria were recruited. An equal number of healthy 
subjects (gender matched) were taken as control group. Subjects from both 
groups with hypertension, diabetes mellitus, hypercholesterolemia, metabolic or 
connective tissue disease, on oral anti- coagulant, oral contraceptive pills, bed 
ridden and smoker were excluded. The CIMT measurement was performed by a 
single operator using an ultrasound machine (Siemen Acuson S2000) with 18 
MHz linear array transducer. Both side of carotid arteries examination was 
performed with the subject in lying positioned and after a 10 minutes rest. An 
independent T-test was performed to compare mean. Regression analysis was 
used to look for association between CIMT and patient’s age, disease duration, 
number of bood transfusion and serum ferittin level. All data analysis was 
performed using IBM SPSS software version 22.0 for Windows. 
 
Results. A total of 80 subjects were included in this study with the equal 
number of thalassemia patients and the normal population. The mean value of 
CIMT of the general population was 0.32± 0.08mm and the mean value of 
thalassemia patient’s CIMT was 0.45± 0.10mm. The independent t-test showed 
statistically significant differences of these measurement (p<0.001). On univariate 
analysis, there is a strong correlation between thalassemia CIMT measurement 
and disease duration and number of blood transfusions. However multivariate 
analysis showed only the number of blood transfusion is correlated with patient 
CIMT measurement. Increased in the number of blood transfusion by 100 times 
will increase the mean CIMT by 1.0mm.  
 
Conclusion: The CIMT measurement among thalassemia patient is 
significantly higher compared to general population and it is associated with the 
numbers of blood transfusion being received. 
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ABSTRAK 
Bahasa Malaysia 
 
Tajuk: Kajian tentang ketebalan ‘carotid intima-media’ di kalangan pesakit 
thalassemia di HUSM. 
 
Latarbelakang: 
Jangka hayat pesakit thalassemia sekarang dapat dilanjutkan dengan adanya 
perkembangan pesat dalam teknologi perubatan dan prasarana kemudahan kesihatan. 
Akibatnya, timbul komplikasi- komplikasi baru dikalangan pesakit thalassemia ini dan 
diantara yang meningkat ialah komplikasi salur darah tersumbat (thromboembolism). 
Kajian menunjukkan ketebalan ‘carotid intima-media’(CIM) yang diukur menggunakan 
mesin ultrasound dapat memberi gambaran dan stratifikasi tentang risiko serangan sakit 
jantung dan angin ahmar. Kajian terdahulu mensyorkan kajian CIM ini dilakukan keatas 
pesakit thalassemia sebagai alat diagnostik awal dan juga dapat mengetahui risiko untuk 
mendapat komplikasi salur darah tersumbat. 
 
Objektif: 
 Bertujuan untuk mengetahui perbezaan ketebalan CIM diantara pesakit thalassemia 
dengan populasi bukan thalassemia. Kajian juga dilakukan untuk mengetahui hubungan 
diantara ketebalan CIM pesakit dengan umur, jangkamasa penyakit, bilangan transfusi 
darah dan kepekatan serum ferritin. 
   
 
 
xi 
 
Kaedah: 
 Kajian telah dijalankan di Jabatan Radiologi, Hospital Universiti Sains Malaysia 
selama 19 bulan daripada Januari 2013 hingga Ogos 2014. Ketebalan CIM diukur oleh 
seorang penyelidik dengan menggunakan transduser selanjar 18MHz (Acuson S2000 
Siemens). Semua pesakit thalassemia yang sedang menerima rawatan atau rawatan 
susulan di HUSM dan bersetuju untuk mengikuti kajian ini telah diambil untuk kajian 
ini. Selain itu umur pesakit, jangkamasa penyakit, bilangan transfusi darah dan paras 
serum ferritin pesakit thalassemia juga diambil dan direkodkan. 
 
Keputusan: 
 Seramai 80 subjek terlibat dalam kajian ini dimana jumlah subjek thalassemia dan 
bukan thalassemia adalah sama. Nilai purata ketebalan CIM pesakit thalassemia adalah 
0.45± 0.1mm dan nilai purata ketebalan CIM populasi bukan thalassemia adalah 0.32± 
0.08mm. Terdapat perbezaan yang signifikan secara statistik diantara nilai purata 
ketebalan CIM pesakit thalassemia dengan populasi bukan thalassemia. Kajian juga 
mendapati terdapat hubungkait yang signifikan diantara bilangan transfusi darah dengan 
ketebalan CIM pesakit thalassemia. Kenaikan 100 kali bilangan transfusi darah akan 
mengakibatkan kenaikan ketebalam CIM pesakit thalassemia sebanyak 1.0mm. 
 
Kesimpulan: 
 Berdasarkan keputusan ketebalan CIM yang telah dibuat, pesakit thalassemia 
mungkin berisiko lebih tinggi berbanding dengan populasi bukan thalassemia untuk 
mendapat serangan jantung dan angin ahmar dan ianya berkait rapat dengan bilangan 
transfusi darah pesakit.   
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ABSTRACT 
 
English 
 
Title: A study of carotid intima-media thickness among thalassemia patients in 
HUSM. 
  
Background: 
 Thalassemia patient lifespan nowadays has been increased significantly compared to 
previously due to the advancement of medical treatment and better healthcare system. 
As a result, more transfusion-related complications are seen, and one of the rising trends 
is the thromboembolic complication. Studies has shown that ultrasound measurement of 
carotid intima-media thickness (CIMT) can be used as a surrogate marker for future 
cardiovascular event and is recommended to be done in thalassemia patient as early 
diagnostic tool and for vascular risk stratification. 
 
Objectives: 
 To compare CIMT measurement between thalassemia patients in HUSM with the 
non- thalassemia population and to find any association between CIMT measurement 
with patient’s age, disease duration, numbers of blood transfusions and serum ferritin 
level. 
 
Methodology: 
 A cross sectional study was done over a period of 19 months from January 2013 until 
August 2014. A single operator performed the ultrasound examination using 18 Mhz 
xiii 
 
linear array transducer (Siemen Acuson S2000) at Department of Radiology, Hospital 
Universiti Sains Malaysia (HUSM). All thalassemia patient who is receiving treatment 
and follow-up at HUSM and consented for the examination, were subjected to the 
measurement of their carotid intima-media thickness (CIMT). Patient age, disease 
duration, numbers of blood transfusion and serum ferritin level were obtained and 
recorded. The same numbers of healthy subject were recruited from the general 
population and their CIMT were also recorded. 
 
Result: 
 A total of 80 subjects were included in this study with the equal number of 
thalassemia patients and the non- thalassemia population. The mean value of CIMT for 
the non- thalassemia population was 0.32± 0.08mm and that of thalassemia patient was 
0.45± 0.10mm. Independent t-test showed statistically significant difference between 
these two measurements (p<0.001). On univariate analysis, there was a strong 
correlation between thalassemia CIMT measurement and disease duration and number 
of blood transfusions. However multivariate analysis showed only the number of blood 
transfusion was significantly correlated with patient CIMT measurement. Increased in 
the number of blood transfusion by 100 times would increase the mean CIMT by 
1.0mm. 
 
Conclusion: 
 The finding of higher mean value of CIMT in thalassemia patient might be suggestive 
for an increased in future cardiovascular and cerebrovascular event in thalassemia 
patient compared to non- thalassemia population and it is significantly associated with 
the number of blood transfusion. 
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1.0 INTRODUCTION 
 
Thalassemia is classified as a group of congenital hereditary blood disorders in 
which the anomalies are within the synthesis of the chains of haemoglobin. The total 
annual incidence of symptomatic individuals is estimated at 1 in 100,000 throughout 
the world and in Malaysia, it is estimated about 4.5% of its population are 
heterozygous carriers for beta- thalassemia and the couples are at risk of having beta 
thalassemic child about 2.1/1000 births annually (George, 2001). Clinical 
presentations of thalassemia range from totally asymptomatic individuals to severe 
anaemia which needs regular blood transfusion. It is estimated that about 4,800 
thalassemia major patients in Malaysia which need regular blood transfusion 
(Elizabeth and Ann, 2011).  
 
Common problem encountered by thalassemia major patient from their 
chronic anaemic state is tissue iron deposition as a result from the frequent blood 
transfusion and increased in gastrointestineal iron absorption. As a consequence, toxic 
iron will accumulate within liver, heart, spleen and endocrine organs. Chelation 
therapy had been commenced to counter iron overload in thalassemia patient and 
desferoxamine mesylate has been the standard treatment for iron chelation therapy for 
decades (Delea et al., 2007). Although current thalassemia patients’ survival has 
increased due to chelation therapy, cardiovascular complications are still common 
(Hahalis et al., 2008) and about 70% of all thalassemic deaths are due to heart failure 
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and arrhythmias (Borgna-Pignatti et al., 2004). This may be due to issue of 
compliancy because of the discomfort during the iron chelating therapy administration 
and due to its high cost (Delea et al., 2007; Dahlui et al., 2009; Viprakasit et al., 
2009). The compliancy of desferoxamine usage had been shown to reduce the serum 
ferritin level as well as cardiac complication (Wolfe et al., 1985).   
 
Besides that, incidence of vascular complications has been reported in 
thalassemia patients, mainly attributed by the hypercoagulable state and vascular 
dysfunction (Hahalis et al., 2008). Atherosclerosis is a formation of an atherosclerotic 
plaque within the arterial lumen. It usually started as lipid-filed macrophages or foam 
cells in the early phase which can be replaced by collagen fibres in later stage. As the 
size of the atherosclerotic plaque increases, it can cause narrowing of the vessel 
lumen.  The thickening of the luminal wall can be detected by several imaging 
modalities especially the intima-media complex which also been called as carotid 
intima media thickness (CIMT). 
 
CIMT can be measured by using ultrasound, computed tomography (CT) scan 
or magnetic resonance imaging (MRI). Ultrasound examination is by far the most 
preferred technique as it is non-radiating and relatively inexpensive. CT scan 
measurement is highly reproducible compared to ultrasound and its measurement can 
be considered as tomographic equivalent of sonographic CIMT (Saba et al., 2008). 
However the radiation hazard from the examination limits its daily usage. MRI 
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examination is another examination which is potential to have higher reproducibility 
(Underhill et al., 2006). However the availability is usually limited compared to 
ultrasound and the cost is much higher.  
 
 Several studies have shown that sonographic carotid intima media thickness 
(CIMT) measurement is increased in thalassemia patients indicating premature 
atherosclerosis. The same studies also shown that sonographic CIMT measurement in 
thalassemic patients’ are correlated with patients’ age (Tantawy et al., 2009), disease 
duration (Dogan and Citak, 2011) and serum ferritin level (Tantawy et al., 2009; 
Ismail and El-Sherif, 2010; Dogan and Citak, 2011). Sonographic CIMT 
measurement, which is a recognised surrogate marker for future cardiovascular events  
(Bots et al., 1997) is recommended to be done in beta thalassemia patients as a non-
invasive early diagnostic tool (Ismail and El-Sherif, 2010; Dogan and Citak, 2011)  
and for vascular risk stratification (Tantawy et al., 2009).   
 
There are few sonographic CIMT measurement studies done on thalassemia 
patients worldwide however there is no similar study has yet to be done in Southeast 
Asia, particularly Malaysia which mainly comprised of HbE β-thalassemia, which is a 
structural β-globin Hb variant with a β+ phenotype (George, 2013). HbE β-
thalassemia shows highest frequencies in Asia such as India, Bangladesh, Thailand, 
Laos, Cambodia (Olivieri et al., 2011) and also in Malaysians’ Malay population 
(George, 2013). By doing this study, it is hoped that the local thalassemia CIMT 
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measurement can be measured and compared with the normal population. Any 
difference in the mean and standard deviation will be analyzed and any increment in 
the CIMT would indicate subclinical atherosclerosis and increased risk of having 
future thrombosis event. If there is evidence of subclinical atherosclerosis in the local 
thalassemia population, than perhaps there would be a role of anti-thrombolytic agent 
in thalassemia patient in the future. Any significant correlation between patient CIMT 
with patient’s age, disease duration, number of blood transfusion and serum ferritin 
level would greatly help us to understand more regarding this new emerging 
complication finding. 
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2.0 LITERATURE REVIEW 
 
 
2.1 Anatomy of the common carotid artery  
 
Both right and left common carotid arteries differ in length and in their mode 
of origin. There are many variants besides the common pattern. The knowledge of the 
normal common carotid artery anatomy and its variants are important during the 
ultrasound assessment. 
 
2.1.1 Vascular anatomy 
The brain received its blood supply mainly from 4 main vessels, right and left 
internal carotid arteries and right and left vertebral arteries. The internal carotid artery 
derived from common carotid artery on each side of the neck. The right common 
carotid artery derives from the brachiocephalic trunk which is the first branch of arch 
of aorta while the left common carotid artery derived directly from aortic arch in the 
superior mediastinum (Figure 2.1). The right common carotid artery has cervical part 
while left common carotid artery has cervical and thoracic part (Standring, 2008). 
 
The brachiocephalic trunk travels superiorly, slightly posterior from the aortic 
arch to the right of the neck for about 4 to 5cm in length before dividing into right 
common carotid artery and right subclavian artery at the upper border of right 
sternoclavicular junction (Zwiebel, 2000). The left common carotid artery travels 
upwards from the aortic arch and passes beneath left sternoclavicular joint. Both 
common carotid arteries then divides into internal and external carotid arteries at the 
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level of upper border of thyroid cartilage (Zwiebel, 2000). Both common carotid 
arteries do not give collateral branches.  
 
2.1.2 Normal variants. 
There are many normal variants of the origin of these vessels (Butler et al., 
2012). The most common appearance of the aortic arch and it normal variations are 
shown in figure 2.1 and figure 2.2. The knowledge of the normal variants is important 
because it might cause difficulties in identifying the respective vessels if present.  
 
 
 
 
Figure 2.1: Moss common appearance of aortic arch. (Adapted from Butler et 
al., 2012) 
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Figure 2.2: Normal variant of the aortic arch and origin of the common 
carotid artery. Key: RS- right subclavian artery, RC- right 
common carotid artery, BT – brachiocephalic trunk LC- left 
common carotid artery, LS- left subclavian artery and LVA- left 
vertebral artery. (Adapted from Butler et al., 2012) 
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2.1.3 Normal arterial wall structure 
Traditionally, based on the basis of size and characteristics of tunica media, 
there are 3 different types of arteries (Pawlina and Ross, 2011) which are the large 
arteries, medium arteries and small arteries or arteriololes. Common carotid artery is 
categorized under large artery and has 3 distinct layers which are the intima or the 
epithelial lining of the artery, media or muscular layer and adventitia. The intima is 
the innermost layer, followed by media which is the middle layer and adventitia, the 
outermost layer (Figure 2.3).  
 
The tunica intima consist mainly of three component; the endothelium which 
is a single layer of squamous epithelial cell; a thin layer of extracellular cell called 
basal lamina which composed of collagen, proteoglycan and glycoprotein; and lastly 
the subendothelial layer which consists of loose connective tissue. Smooth muscle cell 
occasionally can be found within the loose connective tissue. This subendothelial 
layer contained sheet like layer or lamella of fenestrated elastic material called the 
internal elastic membrane. These fenestrations enable substances to diffuse readily 
through the layer and reach cells deep within the wall of the vessel.  
 
The tunica media, or middle layer, consists primarily of circumferentially 
arranged layers of smooth muscle cells (Standring, 2008). This layer has variable 
amounts of elastin, reticular fibers, and proteoglycans which is interposed between the 
smooth muscle cells of the tunica media. It extends from the internal elastic 
membrane to external elastic membrane and is relatively thick. The external elastic 
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membrane is a layer of elastin that separates the tunica media from the tunica 
adventitia. The sheets or lamellae of elastin are fenestrated and arranged in circular 
concentric layers.  
 
The tunica adventitia, or outermost connective tissue layer, is composed 
primarily of longitudinally arranged collagenous tissue and a few elastic fibers. It will 
gradually merge with the loose connective tissue surrounding the vessels. This tunica 
adventitia is relatively thin. Most tunica adventitia layers of large arteries contains a 
system of vessels that supplies blood to the vascular walls themselves called the vasa 
vasorum, as well as a network of autonomic nerves called nervi vascularis that control 
contraction of the smooth muscle in the vessel walls. The main cell in the adventitia 
layer is the smooth muscle cells. Their main function is for structural support of the 
artery. They regulate the size of the arterial lumen and hence the blood flow and blood 
pressure by their contractility responses. The smooth muscle cells also responsible for 
synthesis of all constituents of the arterial wall. It is also capable of endocytosis of 
foreign materials and lipoproteins. Besides that, the smooth muscle cells also produce 
all of the extracellular components of the tunica media. The function of smooth 
muscle cells are summarize in table 2.1. 
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Figure 2.3: Normal arterial wall structure. (Adapted from Pawlina and Ross, 
2011) 
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                      Table 2.1:   Functions of arterial smooth muscle cells 
1. Structural support 
2. Contractile response 
3. Synthetic/ metabolic/ secretory function 
- Actin 
- Myosin 
- Collagen 
- Elastin 
- Microfibrillar proteins 
- Proteoglycans 
- Lipids 
4. Endocytosis 
 
 
2.1.4  Normal vascular endothelium layer structure and functions 
 
The endothelium layer is formed by a continuous layer of flattened, elongated, 
and polygonally shaped endothelial cells that are aligned with their long axes in the 
direction of the blood flow. At the luminal surface, they express a variety of surface 
adhesion molecules and receptors such as low-density lipoprotein, insulin, and 
histamine receptors. Endothelial cells have many functions (Table 2.2). It plays an 
important role in blood homeostasis in which these cells can change their functional 
properties in response to various stimuli. This process, known as endothelial 
activation, is also responsible for the pathogenesis of many vascular diseases 
particularly atherosclerosis. Inducers of endothelial activation include bacterial and 
viral antigens, cytotoxins, complement products, lipid products, and hypoxia. 
Activated endothelial cells exhibit new surface adhesion molecules and produce 
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different classes of cytokines, lymphokines, growth factors, and vasoconstrictor and 
vasodilator molecules, as well as molecules that control blood coagulation. 
Endothelial cells also participate in the structural and functional integrity of the 
vascular wall.  
 
Apart from that, endothelial cells are also active participants in a variety of 
interactions between the blood and underlying connective tissue and are responsible 
for many properties of the vessels. First, endothelial cells exhibit a selective 
permeability barrier which allows selective movement of small and large molecules 
from the blood to the tissues and from the tissues to the blood. This movement is 
related to the size and charge of the molecules. Through a process called simple 
diffusion, small hydrophobic (lipid-soluble) molecules such as oxygen or carbon 
dioxide can readily pass through the permeable lipid bilayer of the endothelial cell 
membrane. However, water and hydrophilic (water-soluble) molecules such as 
glucose, amino acids and electrolytes cannot diffuse across the endothelial cell 
membrane and these molecules and solutes have to be actively transported. Secondly, 
the endothelial layer functions as a nonthrombogenic barrier between blood platelets 
and subendothelial tissue which is done by producing anticoagulants and 
antithrombogenic substances. Normal endothelium does not support the adherence of 
platelets or the formation of thrombi on its surface. However, damaged endothelial 
cells cause them to release prothrombogenic agents such as von Willebrand factor or 
plasminogen-activator inhibitor to promote thrombus formation. The modulation of 
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blood flow and vascular resistance is achieved by the secretion of vasoconstrictors 
such as endothelins, angiotensin-converting enzyme, prostaglandin, thromboxane and 
vasodilators such as nitrous oxide (NO).  
 
The contraction and relaxation of smooth muscle cells in the tunica media 
influencing local blood flow and pressure also is being controlled by the endothelium 
layer. Shear stress produced during the interaction of blood flow with vascular 
endothelial cells initiates nitric oxide-derived relaxation of blood vessels. 
Endothelium-derived nitric oxide is one of several critical regulators of cardiovascular 
homeostasis. It regulates the blood vessel diameter, inhibits monocyte adhesion to 
dysfunctional endothelial cells, and maintains an antiproliferative and anti-apoptotic 
environment in the vessel wall. Nitric oxide is an endogenous vasodilatory gas which 
continuously being synthesized in endothelial cells by endothelial nitric oxide 
synthase (eNOS). It acts as an anti-inflammatory agent under normal physiologic 
conditions, although its overproduction induces inflammation. Nitric oxide is also 
involved in immune reactions, a potent neurotransmitter in the nervous system, and 
also contributes to the regulation of apoptosis.  
 
Other function of endothelial cell includes regulation and modulation of the 
immune responses. It also synthesizes, metabolizes and secretes many substances, 
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such as prostacyclin, angiotensin-converting enzyme, clotting factor VIII and 
lipoprotein lipase. 
 
Table 2.2: Functions of endothelial cells 
1. Blood compatible container 
2. Selective permeability barrier 
3. Synthetic/ metabolic/ secretory function 
- Angiotensin-converting enzyme 
- Factor VII 
- Plasminogen 
- Von-Willebrand factor 
- Prostacyclin 
- Thromboxane 
- Fibronectin 
- Collagen (type IV) 
- Α-2-macroglobulin 
- Lipoprotein lipase 
- Hormone receptors 
4. Binding and internalization of lipoproteins 
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 2.2 Atherosclerosis 
Atherosclerosis is the process of atherosclerotic plaque formation within the 
arterial lumen. Atherosclerotic plaques can be characterized by tunica intimal 
thickening due to progressive accumulation of lipids together with numerous cellular 
and molecular components such as smooth muscle cells (SMC), lipid-filled 
macrophages, monocytes, T and B lymphocytes, erythrocytes, and platelets 
(Nicolaides et al., 2011). American Heart Association (AHA) Committee on Vascular 
Lesion has divided plaques into six stages according to the plaque composition and 
morphology based on histologic studies of human vessels, mainly coronary and aortic 
arteries obtained at autopsy.  
 
 
 2.2.1 Early Lesions (Types I and II) 
These plaques appear during the first decades of life and usually do not cause 
substantial luminal stenosis. In type I plaques, the histological changes are minimal, 
which consist of isolated groups of lipid-filled macrophages or foam cells that are 
visible only with microscopic examination (Figure 2.4). These are in contrast to type 
II plaques or fatty streaks which are visible on gross examination and contain 
increased numbers of foamy macrophages. It will become stratified into layers 
together with some foamy smooth muscle cells (Figure 2.4). The main source of 
plaque lipids is the circulating LDL particles that become entrapped within the 
subendothelial layer as evidence by the strong similarity between the chemical 
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composition of the low-density lipoprotein (LDL) particles and plaque lipids. The 
process in which LDL particles can appear within the vessel wall is either by passive 
diffusion through the endothelium or by receptor-mediated endocytosis. 
Subsequently, through ionic interactions between the apolipoprotein-B of the LDL 
particle and matrix proteoglycans, collagen fibers, and fibronectin found in the vessel 
wall, retention of LDL particles within the vessel wall will occur. The trapped LDL 
particles will then undergo extensive modifications such as oxidation, proteolysis, 
aggregation, and lipolysis. Minimally oxidized LDL particles (mmLDL) are 
recognized by the LDL receptor, and their accumulation will stimulate endothelial 
cells to promote recruitment of monocytes and lymphocytes to the vessel wall. 
Severely oxidized LDL particles in contrast, can only be recognized by scavenger 
receptors that are expressed on macrophages and vascular smooth muscle cells. The 
uptake of oxidized LDL will cause formation of foam cells (Figure 2.4). 
 
 
 2.2.2    Preatheroma/Intermediate Lesions (Type III) 
Type III plaques have a histological appearance that is in between the early 
fatty streaks and the first advanced lesion type or atheroma. However, it is not known 
how the plaques progress from one stage to the other, whether it progress linearly or 
not. In type III plaques, organized histological layers can be seen. Foamy cells are 
present at the luminal side with tissue degeneration region seen in the middle layer 
and scattered extracellular lipids noted at the base of the plaque (Figure 2.4). Type III 
plaques contain more free cholesterol, fatty acids, triglycerides, sphingomyelin, and 
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lysolecithin than type II plaques. An intermediate type of plaque can directly 
transform into an advanced and more complicated lesion. 
 
 
2.2.3 Advanced Atherosclerotic Plaques (Atheroma-IV, Fibroatheroma-Va, 
Calcific-Vb and Fibrotic-Vc) 
In type IV plaque or atheroma, there is abundant accumulation of extracellular 
lipids is seen. The lipids form a consolidated core located deeply within the intima 
and disorganizes the extracellular matrix. The region of the thickened intima between 
the lipid core and the endothelial surface contains smooth muscle cells, macrophages 
with and without lipid droplets, T lymphocytes and mast cells (Figure 2.4). 
Proteoglycan will be secreted by the smooth muscle cells in and few collagen fibers 
may gradually thicken at the region above the lipid core. At the base of the atheroma, 
cell death and formation of a necrotic core will occurs which is rich in cellular debris 
and crystalline cholesterol. Atheroma usually do not cause severe luminal narrowing, 
however there are susceptible to fissure formation and ruptures to become a 
complicated plaque due to their surface composition. 
 
Fibroatheromas or type Va plaques have a thick layer of fibrous connective 
tissue. It mainly contains collagen fibers and rough endoplasmic reticulum–rich 
smooth muscle cells at the luminal side of the intima which is called the fibrous cap. 
It separates the lipid core from circulating blood constituents. The capillaries at the 
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borders of the lipid core may be larger and more numerous compared to those found 
in type IV plaques. 
 
Type Vb plaques or calcified plaques is characterized by increased in its 
mineralization. In type Vc or fibrotic lesions, the intima thickening is primarily due to 
accumulation of collagen fibers instead of lipid accumulation. Type V plaque can 
suddenly transform to type VI plaque with formation of surface defects like erosions, 
fissures and ruptures or with the formation of hematomas. 
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Figure 2.4: Histological examples of atherosclerotic plaque types classified 
according to the American Heart Association criteria (Adapted 
from Nicolaides et al., 2011).  
(a) A crescent-shaped type I intimal thickening. Pgc=proteoglycan intima layer, me= 
musculoelastic intima layer, M=media, A=adventitia, lumen=lumen of the artery 
(b) A type II (progression-prone fatty streak) lesion. Macrophage foam cells (fc) 
occupy the intima at the junction of the proteoglycan (pgc) and musculoelastic (me) 
intima layers, e=endothelial cells at the artery lumen, M=media, A=adventitia.  
(c) A type III (preatheroma) lesion. Extracellular lipid (arrows) is pooled in the 
musculoelastic layer (me). Smooth muscle cells, normally closely packed, are 
separated, compressed, and attenuated by the extracellular lipid. Macrophage foam 
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cells (fc) are some distance above the pooled extracellular lipid, endothelial cells (e) 
at the artery lumen, pgc= proteoglycan intima, M= media, A= adventitia.  
(d) A type IV (atheroma) lesion. In addition to all the changes seen in type IIa and III 
lesions, a massive aggregate of extracellular lipid (lipid core) occupies the 
musculoelastic layer (me). Macrophage foam cells (fc) are above the lipid core. Pgc= 
proteoglycan intima layer, M=media, A=adventitia 
(e) A type V (fibroatheroma) lesion in the distal part of the abdominal aorta. The part 
of the lesion above the lipid core and above the layer of macrophage foam cells (fc) 
consists of dense bands of collagen, endothelial cells (e) at the artery lumen, M= 
media,  
(f) A type VI (complicated) lesion in the distal recruited through the activated 
endothelium differentiate into macrophages. Several endogenous and microbial 
molecules can ligate pattern-recognition receptors on these cells, inducing activation 
and leading to the release of inflammatory cytokines, chemokines, oxygen and 
nitrogen radicals, and other inflammatory molecules and, ultimately, to inflammation 
and tissue damage  
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2.3 Thalassemia 
Thalassemia syndromes are inherited disorders due to abnormal α or β-globin 
biosynthesis. The reduce supply of globin will reduce production of haemoglobin 
tetramers, leading to hypochromia and microcytosis. The synthesis of the unaffected 
globins proceeds at normal rate will cause unbalanced accumulation of alpha or beta 
subunits.  Normally all four alpha genes and both beta genes are active in the 
production of globin chains. In beta thalassemia, synthesis of the beta chain is 
defective where as in alpha thalassemia, the synthesis of the alpha chain that is 
defective. Beta thalassemia is common in the Mediterranean region and in portions of 
Africa, Asia, the South Pacific, and India while alpha thalassemia is most common in 
Southeast Asia. Thalassemia patients have a wide spectrum of clinical presentations, 
ranging from totally asymptomatic to severe anaemia which need regular blood 
transfusion. This depends on the degree to which the synthesis of the affected globin 
is impaired, altered synthesis of other globin chains and coinheritance of other 
abnormal globin alleles (Longo, 2013).  
 
In beta thalassemia, point mutations or a partial deletion of chromosome 11 
cause defective synthesis of the beta chain. Over 100 mutations have been identified. 
Normally alpha and beta globin chains are made approximately in equal amounts. 
When beta globin chains are in short supply or absent, as in beta thalassemia, alpha 
chains are in excess. The excess alpha chains combine with other available beta 
family globin chains (delta or gamma) to form increased amounts of Hgb A2 (α2 δ2) 
and Hgb F (α2 γ2). Hgb Barts (γ4) or tetramers of excess gamma chains may also 
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form (Figure 2.5). Because of the reduced amounts of haemoglobin tetramers, all beta 
thalassemia haemoglobin are characterised by hypochromic and microcystosis. In 
heterozygotes or known as beta thalassemia trait, this is the only abnormality seen and 
the anaemia is usually minimal. In more severe form of homozygous state, there will 
be highly insoluble unpaired alpha chains due to unbalanced alpha and beta-globin 
accumulation. This in turn will form toxic inclusion bodies that kill developing 
erythroblast in the marrow. Few erythroblasts will survive and mature and it will then 
bear a burden of inclusion bodies that are detected in the spleen. The red blood cell 
life span will be reduced leading to haemolytic anaemia. Marrows will response with 
increased production of erythroblast however the anaemia will still persist due to 
ineffective erythropoiesis. Based from the abnormal genetic mutation inherited and 
clinical syndromes, four phenotypes of beta-thalassemia had been categorised: beta-
thalassemia carrier, beta-thalassemia trait, beta-thalassemia intermedia and beta-
thalassemia major. Beta-thalassemia carrier and trait are usually asymptomatic, 
whereas beta-thalassemia major needs frequent blood transfusion. Unlike thalassemia 
major, beta-thalassemia intermedia patients usually does not need frequent blood 
transfusions and commonly presented later, during their early adulthood period.  
 
One to four alpha genes may be deleted in alpha thalassemia disorders. The 
clinical manifestations of alpha thalassemia vary with the number of alpha-chain 
genes that are deleted from chromosome 16. If only one alpha gene is deleted, no 
hematologic abnormalities are seen. This is known as a silent carrier state. If two 
alpha genes are deleted, either homozygous (a-/a-) or heterozygous (--/aa), the 
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condition is alpha thalassemia trait. The heterozygous type is encountered in 
Southeast Asian populations, but is rare in Afro-Americans. Alpha thalassemia trait 
results in microcytosis, hypochromia, and mild anaemia. If three alpha genes are 
deleted (--/-a), there will be an accumulation of unpaired beta chains and are soluble 
enough to form β4 tetramers called hemoglobin H (HbH) (Figure 2.6). Patient with 
hemoglobin H disease usually will behave like thalassemia intermedia, characterised 
by moderately severe haemolytic anaemia but milder ineffective erythropoiesis. It 
also common for the patient to survive to mid-adult life without needing blood 
transfusion. If all four of the alpha genes are deleted, it is called hemoglobin Barts 
which is incompatible with life and usually results death in utero. The red blood cells 
contain only Bart's haemoglobin, a tetramer of gamma chains which is incompatible 
with life. This condition which also known as hydrops fetalis is usually encountered 
in Asian and African population. 
 
 
Figure 2.5: Type of beta thalassemia. (Source: http://www.med-
ed.virginia.edu/courses/path/innes/rcd/thalassemia.cfm)  
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Figure 2.6: Type of alpha thalassemia. (Source: http://www.med-
ed.virginia.edu/courses/path/innes/rcd/thalassemia.cfm)  
 
 
2.4 Hypercoagulability State in Thalassemia Patient 
Due to the better health care support, current thalassemia patient lives longer 
compared previously. As a result, new complication were identified in this type of 
patient and the commonest problem that had been increasingly recognised is 
thromboembolic events (Taher et al., 2008) (Panigrahi and Agarwal, 2007). An Italian 
multicentre study (Borgna Pignatti et al., 1998) revealed that 27 of 683 (3.95%) 
thalassemia major and 5 of 52 (9.61%) thalassemia intermedia patient developed 
thromboembolic events. About half the events involved central nerve system (CNS) 
location, followed by deep vein thrombosis (DVT) (25%), pulmonary (9.3%), portal 
(6.3%) and intracardiac (6.3%). Another study done in Mediterranean regions and 
Iran (Taher et al., 2006) showed that 146 out of 8860 (1.65%) thalassemia patient had 
experienced thromboembolic event, 61 with thalassemia major (0.9%) and 85 with 
thalassemia intermedia (3.9%). According to the study, the highest occurrence of 
thromboembolic events that occur in thalassemia were deep vein thrombosis (32%), 
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followed by stroke (18%), portal vein thrombosis (16%), pulmonary embolism (13%) 
and superficial thrombophlebitis (4.7%). The study also noted that venous thrombosis 
was more common in thalassemia intermedia while arterial events were significantly 
more in thalassemia major patients. Thrombosis was noted more common in female, 
splenectomised patients and those with profound anemia. 
 
There are many factors contributing to the hypercoagulable state in 
thalassemia patients (Table 2.3). The first factor is platelet abnormalities. Many 
studies have showed that there is impairment of platelet aggregation, increased in 
circulating platelet aggregates and shortened platelet lifespan (Eldor and 
Rachmilewitz, 2002; Panigrahi and Agarwal, 2007; Taher et al., 2008; Cappellini et 
al., 2010). There is also chronic platelet activation in patient with thalassemia, which 
is more pronounced in patient with beta thalassemia undergoing splenectomy.  
 
Apart from that, there are defects in coagulation inhibitors and plasma markers 
in thalassemia major patients. Irrespective of the patient’s age, the coagulation 
inhibitors-protein C (PC) and protein S (PS) are significantly decreased in patients 
with thalassemia major. Study done among thalassemia major patients in Hospital 
Universiti Sains Malaysia also showed similar result when compared to normal blood 
donors (Rosnah et al., 2014). Some thalassemic patient from Italy and Turkey had low 
antithrombin III (AT III) in addition to protein C and protein S deficiency. Heparin 
co-factor II (HC II) which is another coagulation inhibitor, is also low in thalassemia 
patients, and this is known to be associated with increased thrombotic risk.  
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Red blood cells also play roles in the hypercoagulability state in thalassemia 
patient. The oxidation of globin subunits in thalassemia erythroid cells will alter the 
red blood cells leading to the formation of hemichromes. Hemichromes bind to or 
modify various components of the mature red blood cell membrane. Heme will 
disintegrate after the precipitation of hemichromes, and toxic nontransferrin-bound 
iron species are released from the heme disintegration. The free iron will then 
catalyzes the formation of reactive oxygen species which in turn cause thalassemic 
red cells to become rigid and deformed and to aggregate, resulting in premature cell 
destruction. Studies also have shown that thalassemic red blood cells may be a source 
of negatively charged phospholipids (Eldor and Rachmilewitz, 2002; Panigrahi and 
Agarwal, 2007; Taher et al., 2008; Cappellini et al., 2010), which can eventually 
increase thrombin generation. Several studies have also demonstrated that RBCs from 
thalassemic patients show enhanced cohesiveness and aggregability which will be 
reduced to normal range after the patients have received a blood transfusion. 
 
Due to increase in haemolysis process, plasma iron and hemin levels are 
elevated in beta thalassemia patients. This will lead to generation of labile iron at the 
inner and outer cell surfaces, exposing the cell to conditions whereby the labile metal 
promotes the formation of reactive oxygen species (ROS). This will lead to 
cumulative cell damage. Higher ROS levels were seen in patient with beta 
thalassemia compared to normal blood donors suggesting that there is a chronic 
oxidative stress in patients with β-thalassemia. This will leads to platelet activation 
and susceptibility to thromboembolic consequences.  
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Thalassemia patients also have inherited prothrombotic mutations such as 
heterozygosity for Factor V Leiden, MTHFR C677T homozygosity and prothrombin 
G20210A mutation leading to hypercoagulability state. Other contributing factors for 
thromboembolic events are associated abnormalities like dilated cardiomyopthy, 
hypothyroidism and hyperglycemia.  
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Table 2.3: Causes of hypercoagulable state in thalassemia patient 
1. Red blood cells 
- Abnormal erythoid cells 
- Source of procoagulant phospholipids 
- Enhanced cohesiveness 
2. Platelets 
- Increased platelet aggregations 
- State of oxidative stress 
- Expression of activation markers 
3. Abnormal coagulation profile 
- Decreased Protein C, Protein S and anti-thrombin III 
4. Iron overload 
5. Endothelial damage 
6. Hyperviscosity 
7. Genetic mutations 
- Factor V Leiden 
- Prothrombin  
8. Others 
- Cardiac dysfunction 
- Liver dysfunction 
- Hormonal deficiencies 
- Antiphospholipid antibodies 
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2.5 Radiological Investigation of Carotid Diseases. 
 There are many radiological carotid diseases imaging techniques which 
include ultrasound, computed tomography angiography (CTA), MRI and digital 
subtraction angiography (DSA). Ultrasound is by far the most widely employed 
imaging modality and the screening method of choice because it is relatively 
inexpensive, portable, and completely non-invasive, it can be repeated as often as 
necessary, and it has good diagnostic accuracy for the detection of significant 
stenosis.  However its evaluation is restricted to a limited portion of the carotid artery, 
image quality is not always optimal, and reproducibility is limited because of 
operator- dependent factors. Thus, there is substantial variability in the performance 
of the test amongst different centres (Jahromi et al., 2005).  
 
DSA has been the confirmatory imaging modality before surgical intervention 
for many years, and still it is considered as the reference standard for the detection 
and quantification of carotid stenosis until today. However it is invasive in nature with 
possible of neurological and vascular complications (Willinsky et al., 2003). DSA 
also involved in using ionizing radiation and nephrotoxic contrast agents which may 
be limited in patients with renal disease, and it is expensive and relatively lengthy.  
 
CTA is an alternative to DSA which is less invasive. With the newer 
generations of multidetector spiral scanners, CTA can provide complete three- 
dimensional (3D) coverage of the carotid tree which is highly accurate in detecting 
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luminal stenosis (Koelemay et al., 2004). Study also showed that carotid artery wall 
thickness can be measured by this method and can be considered the tomographic 
equivalent of CIMT measured by ultrasound (Saba et al., 2008)  However it also have 
its limitation due to radiation exposure and risk of contrast-induced nephrotoxicity.  
 
MRI has emerged as the most widely employed non-invasive modality if a 
confirmatory test is needed after ultrasound examination. MRI does not involve in 
ionizing radiation and there is less significant nephrotoxicity of routine contrast 
agents (gadolinium chelates) at common doses. Image quality is good with high 
spatial, temporal, and contrast resolution. Another advantage is the versatility to 
perform different types of imaging that highlight specific anatomy or functions, 
making MRI equally suitable for angiography, flow quantification, wall depiction, or 
even brain imaging in the same setting. Complete carotid circulation including 
extracervical segments can be examined, and 3D acquisitions can be evaluated. 
Furthermore study has shown that there is a high correlation between sonographic 
CIMT measurements with mean wall thickness measured by MRI which is potential 
to have higher reproducibility (Underhill et al., 2006). However patients need to be 
capable of lying flat for a longer period of time and follow simple instructions, as 
movement will result in image quality degradation.  Severe claustrophobia, obesity, 
advanced kidney disease and incompatible metallic implants or electronic devices are 
also contraindicated in MRI.  In addition, the availability of MRI is usually limited as 
compared to ultrasound, and the cost is much higher. 
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2.6 Sonographic B-Mode Examination of Carotid Intima-Media Thickness 
(CIMT) 
 
Pignoli et al in 1986 has shown that CIMT sonographic measurement did not 
differ significantly from the intima-medial thickness measured on pathologic 
examination. By using a high frequency transducer, longitudinal B-scan of the 
common carotid artery is performed and the distance between two echogenic lines in 
the far wall of the artery is measured as CIMT (Pignoli et al., 1986).  As technology 
advanced, near wall and far wall of the carotid artery can be visualised by ultrasound 
(Figure 2.6),  however B-mode evaluation of the near wall is less reliable than the far 
wall (Touboul, 2002). This can be explained by the ultrasound physic principal in 
which the anatomic location of an interface corresponds to the image interface only 
when the ultrasound beam comes from a less more dense tissue (Plavnik et al., 2000). 
Thus the leading edge of the near wall has no anatomic relevance between the media-
adventitia and the lumen interface. For young adult CIMT measurement, the 
reproducibility is greatest when combining values from both carotid arteries 
(Gonzalez et al., 2008).  
 
A meta-analysis of 8 observational studies which involved 37,197 subjects 
who were followed up for a mean of 5.5 years revealed that by increment of 0.1mm in 
CIMT, the future risk of stroke increases by 13-18% and the myocardial infarct risk 
increases by 10-15% (Lorenz et al., 2007). Conditions associated with increased 
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CIMT are familial hypercholesterolemia, hypertension, obesity, diabetes, metabolic 
syndrome, HIV, Kawasaki disease (Urbina et al., 2009). 
 
 
 
 
 
Figure 2.7: B-mode sonography of common carotid artery showing near wall 
and far wall. (Adapted from O’Leary and Bots, 2010)  
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3.0 OBJECTIVES 
 
3.1 General Objective: 
To measure carotid intima media thickness among thalassemia patient in HUSM 
 
 
3.2 Specific Objectives: 
1. To compare sonographic CIMT measurement between thalassemia patients in 
HUSM and non- thalassemic population. 
2. To look for association between CIMT measurements of thalassemia patient in 
HUSM and patient’s age, disease duration, number of blood transfusions and 
serum ferritin level. 
 
3.3 Hypothesis 
Null hypothesis: 
There is no difference in sonographic CIMT value between thalassemia patients in 
HUSM and non- thalassemic population. 
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4.0 VALIDATION STUDY 
4.1 INTRODUCTION 
A validation study was performed prior to main research to validate the 
researcher’s measurement of intima-media thickness and to determine its 
reproducibility. Both inter and intra-observer variability was tested in this study. 
 
4.2 OBJECTIVES 
The study was aimed to determine the inter-observer and intra-observer 
reproducibility of the IMT measurements performed by the researcher. 
 
4.3 METHODOLOGY 
The study was conducted in Department of Radiology, Hospital Universiti 
Sains Malaysia, Kubang Kerian using Siemen Acuson S2000 ultrasound machine 
with a 18 Mhz linear array transducer. The focus, depth and gain were 
standardized by employing the incorporated program within the ultrasound 
equipment. 
 
Ten healthy volunteers were recruited from friends and staff from 
Department of Radiology, Hospital Universiti Sains Malaysia for the validation 
study. All volunteers were non-smoker with no history of hypertension, diabetes, 
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hypercholesterolemia, not on oral contraceptive pills and no history of neck 
trauma. The procedure was explained to all the participants and verbal consent 
was obtained. Two observers were involved in this study: the researcher, 
(observer A) and a consultant radiologist, (observer B). 
 
Each subject underwent two examinations on the same day by observer A 
to determine the intraday reproducibility and other examinations by observer B to 
determine the inter-observer reproducibility of the intima-media thickness 
recordings. The observers were blinded to each other’s findings. All the 
volunteers underwent another examination on a different day to determine the 
interday reproducibility of observer A recordings.  
 
4.3.1 Technique 
4.3.1.1 Subject preparation 
Subject was rested for 10 minutes before proceeding with ultrasound 
examination 
 
4.3.1.2 Subject positioning 
i. Subject positioned on supine position. 
ii. The ipsilateral shoulder is drop as far as possible and 
subject’s head is rotated away from the side of being 
examined for maximum neck area exposure for the 
ultrasound examination. 
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iii. To facilitate vessel visualization, subject’s head and neck 
position was adjusted accordingly during the ultrasound 
examination 
 
4.3.1.3 Measurement 
The measurement of intima-media thickness was made in 
longitudinal plane of common carotid artery at the point of 1.0cm 
from the carotid bulb. Carotid bulb is defined as the point where the 
far wall deviated away from parallel plane of distal common carotid 
artery. 
Intima media thickness is defined as the distance between two 
echogenic lines located at the far wall. The first echogenic line 
represents the blood-intima interface while the second echogenic line 
represents media-adventitia junction. After freezing the image, the 
measurement was made with electronic calipers. The screen was 
unfreezed and the site of measurement was relocated before another 
measurement was made. Three measurement were made on each side 
and mean value was then calculated. 
 
4.3.2 Statistical Method 
All data were validated using IBM SPSS Statistic software (v 22.0) 
for Windows. 
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4.4 FLOW CHART 
 
 
 
Subjects identified 
 
- Smoking 
- History of hypertension, diabetes mellitus, 
   hypercholesterolaemia 
- On oral contraceptive pills 
- History of trauma to the neck 
 
No 
 
Yes 
 
Ultrasound examination 
 
Dropped from study 
 
Consented 
 
No 
 
Yes 
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4.5 RESULT 
 
For intra-observer reliability, reliability analysis was performed with Case 
1 ICC (1): one-way random model, single measure. Three measurements were 
made for each subject on each side of the neck. For left neck, the intraclass 
correlation was of 0.67 (95% CI: 0.329, 0.892). As for the right neck, the 
intraclass correlation was of 0.62 (95% CI: 0.263, 0.873). Results are summarized 
in table 4.1. 
 
Table 4.1: Intra-observer reliability with Case 1 ICC (1): one-way random 
model, single measure. 
 
 
Intraclass 
correlation 
(single 
measure) 
95% 
Confidence 
interval 
Left 
neck 
0.67 0.329, 
0.892 
Right 
neck 
0.62 0.263, 
0.873 
 
 
For inter-observer reliability, reliability analysis for the measurement 
made by researcher and consultant radiologist was performed with Case 3 ICC (A, 
1): two-way mixed model, single measure. For left neck, the intraclass correlation 
obtained was of 0.946 (95% CI: 0.809, 0.986) and for the right neck, the intraclass 
  
39 
correlation obtained was of 0.964 (95% CI: 0.87, 0.991). Results are summarized 
in table 4.2. 
 
 
Table 4.2: Inter-observer reliability with Case 3 ICC (A, 1): two-way 
mixed model, single measure. 
 
 
 
 
 
 
4.6 DISCUSSION 
 
For left neck, the measurement made by researcher is of good reliability 
with Case 1 ICC (1) of 0.67 (95% CI: 0.329, 0.892). As for the right neck, the 
measurement made by researcher is of good reliability with Case 1 ICC (1) of 
0.62 (95% CI: 0.263, 0.873). 
 
As for inter-observer reliability, reliability analysis for the measurement 
made by researcher and consultant radiologist was performed with Case 3 ICC (A, 
 Intraclass 
correlation 
(single 
measure) 
95% 
Confidence 
interval 
Left 
neck 
0.946 0.809, 
0.986 
Right 
neck 
0.964 0.87, 0.991 
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1): two-way mixed model, single measure. For left neck, the intraclass correlation 
obtained was of 0.946 (95% CI: 0.809, 0.986) which suggests a very good 
agreement between researcher and consultant radiologist. As for the right neck, 
the intraclass correlation obtained was of 0.964 (95% CI: 0.87, 0.991) which 
suggests a very good agreement between researcher and consultant radiologist. 
 
In conclusion, this study described that the measurement of the intima- 
media thickness of the common carotid artery performed by researcher was as 
accurate as the consultant radiologist. Hence the author was eligible to perform 
the examination on his own. 
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5.0  METHODOLOGY 
5.1 Study Design 
Cross sectional study using ultrasound measuring carotid intima media thickness 
among patient with beta thalassemia in HUSM and non-thalassemic populations. 
 
5.2 Reference Population   
Hospital Universiti Sains Malaysia (HUSM) 
 
5.3 Source Population 
All thalassemia patients who is being treated or follow-up in HUSM that fulfill all 
the criteria. 
 
5.4 Study Period 
19 months (January 2013 – August 2014) 
 
 
5.5 Place of Study 
Department of Radiology, PPSP, USMKK 
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5.6 Ethical Consideration 
Ethical clearance and informed consent were taken for all patients who were 
eligible for the study. This study is fully explained to the subjects by the 
researcher and signed informed consent forms (Appendix 1) were kept for record.  
 
 
5.7 Sampling Method   
Convenient samplings in which all thalassemia cases from haematology ward or 
clinic are screened for the study. Subjects who are eligible will be given 
Questionnaire A before proceeding to ultrasound examination. 
 
 
5.8 Inclusion and Exclusion Criteria 
 
5.8.1    Inclusion Criteria 
1. For thalassemia patient: all thalassemia patients who seek 
treatment in HUSM 
2. For non-thalassemia population: all non- thalassemia 
individuals from general population. 
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5.8.2 Exclusion Criteria 
1. Subject who has being diagnosed for hypercholesterolemia, 
hypertension, diabetes mellitus, metabolic or connective 
tissue disease. 
2. Subject who is on anti- coagulant, oral contraceptive pills 
and bed ridden 
3. Subject is a smoker. 
4. Subject who has history of trauma to the carotid arteries. 
 
 
5.9 Research Tools 
1. Questionnaires 
A short questionnaire, Questionnaire A (Appendix 2) will be given to each 
eligible subject before proceeding to ultrasound examination.  
2. US machine Siemens Acuson S2000 (Siemens, Erlangen, Germany) 
3. Medical records 
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5.10 Sample Size Calculation 
 
Objective 1 
Using PS Power and Sample Size Calculations software (Version 3.0.1, 
January 2009), sample size were calculated based on 2 means. 
 
n = 2 σ 2  ( Zα + Zβ)2  
       Δ2 
 
α = 0.05 
Power, Zβ = 0.8 
Difference of CIMT measurement between thalassemia and normal 
population, Δ = 0.1 (G.Hahalis et al, 2008) 
Standard deviation of CIMT among thalassemia patient, σ = 0.07 
(G.Hahalis et al, 2008) 
 
Sample size calculated = 32/ group 
20% dropout = 38 samples/ group 
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Objective 2 
Using Stata (Version 11.0) software, sample size for objective 2 is calculated 
based on regression analysis (age variable). 
Alpha, α    = 0.0500 (two sided)  
power      = 0.8000  
alt sloop of age (β)   = 0.4000 (G.Hahalis et al, 2008) 
Residual sd     = 7.0305 
Standard deviation of age     = 7.0000 (G.Hahalis et al, 2008) 
Correlation between CIMT and age  = 0.3700 (G.Hahalis et al, 2008) 
 
Calculated sample size, n = 50/ group 
20% dropout = 60 samples/ group 
Total sample size: 60 samples/ group 
 
 
 
5.11   Data Collection and Statistical Analysis 
5.11.1  Objective 1 
Scan technique 
Examinations were performed with subjects in supine position after ten 
minutes rest period. Volunteers were asked to drop the ipsilateral 
shoulder as much as possible and to tilt and rotate their head away 
from the side of examination to maximize exposure of the region of 
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interest. Adjustment to the position of the subject head and neck was 
made during the examination to facilitate vessels visualization. 
Researcher sat on the right side of the patient (figure 5.1); with the 
ultrasound gel applied on the ultrasound probe, examination of the 
common carotid artery were commenced by putting the probe in the 
anterolateral position of the subject’s neck. Both common carotid 
arteries were examined in their full visible length. 
 
Measurement 
In B-mode ultrasonography, several layers of echogenicity 
representing layers of vessel wall can be visualized. Because of 
inability to differentiate between the intima and media layer in 
ultrasound, the measurement of the combined thickness of intima and 
media is used, known as intima-media complex. All IMT 
measurements were made in longitudinal plane. The point with the 
maximum thickness on the far wall of common carotid artery along  
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Figure 5.1: Patient positioning for the ultrasound examination. Arrow indicates 
ultrasound probe placement. 
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1cm section proximal to the carotid bulb is taken.  After freezing the 
image, the measurement was made with electronic calipers. 
Magnification of the ultrasound image was used to improve accuracy 
of placement of the calipers. The first echo along the far wall is derived 
from the lumen/intima interface, while the second echogenic line 
represents the media/ adventitia interface (Sidhu and Desai, 1997). The 
combined intima- media is thus the hypoechoic region between the two 
echogenic lines (figure 5.2). Measurements were repeated three times 
on each side. On each occasion, image will be unfreeze and relocated 
to the position of the maximal intima-media thickness. A total of 6 
readings for each subject will be taken. The mean values of the 6 
readings are taken representing the mean IMT for the subject.  All data 
were recorded on the data collection sheet (Appendix 3 and 4). Data 
were analyzed for mean and standard deviation for each group 
(thalassemia and general population). Then, data normality and 
homogenicity of variance were checked using histogram and Levene’s 
test respectively before using independent T-test. All data analysis 
were done using IBM SPSS Statistic software version 22.0 for 
Windows package program. P value of less than 0.05 was considered 
as significant. 
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Figure 5.2: Carotid intima-media thickness measurement on the far wall, 
proximal to the carotid bulb. The distant between the 2 yellow 
lines is taken as CIMT measurement. (Adapted from O’Leary 
and Bots, 2010)  
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5.11.2 Objective 2 
Thalassemia patient’s age, disease duration, number of blood 
transfusion and serum ferritin level are collected from questionnaire A 
(Appendix 2) and patient’s medical record folder which were recorded 
on the data collection sheet (Appendix 4). The data were analyzed 
statistically for any association with patient’s CIMT measurement 
using multiple linear regression analysis. IBM SPSS Statistic software 
version 22.0 for Windows will be used. 
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5.12 Flow Chart 
 
 
 
 
 
 
 
    
 
          
 
 
 
 
    
Thalassemia patient seen at 
clinic or ward 
Subjects who meet inclusion 
criteria 
Subject with exclusion criteria 
 
Consented 
 
Dropped from study 
Ultrasound performed 
Questionnaire A 
 
Not consented 
Patient/ subject can return to 
ward/ home 
Subject from general 
population 
Subject without exclusion criteria 
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6.0 RESULTS 
Data analysis was performed using IBM SPSS software version 22.0 for Windows. 
Prior conducting the desired test, descriptive analysis was performed to summarize 
the nature of the collected data. Overall, 80 samples were collected. There were equal 
samples representatives from non- thalassemia group as well as thalassemia group.  
 
6.1 Demographic Data 
 
In the non- thalassemia group, 52.5% of the subjects are female while the rest 
47.5% are male (Figure 6.1); with Malay contributes up to 67.5% while the rest of the 
subject are Chinese (32.5%) (Figure 6.2). The mean age for the non- thalassemia 
group is 19.1 years (Figure 6.3).  
 
For the thalassemia group, male subjects are slightly higher with 52.5% 
compared to female (47.5%) (Figure 6.4). Malay contributes up to 92.5% in the 
thalassemic group; followed by Chinese (5%) and Siamese (1%) (Figure 6.5). Mean 
age of the collected samples is 15.7 years old (Figure 6.6). 
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47% 
53% 
Figure 6.1: Gender distribution among non- thalassemia group 
Male 
Female 
68% 
33% 
Figure 6.2: Race distribution among non-thalassemia group 
Malay 
Chinese 
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Figure 6.3: Mean age among non- thalassemia group. 
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47% 
53% 
Figure 6.4: Gender distribution among thalassemia group 
Male 
Female 
67% 
32% 
1% 
Figure 6.5: Race distribution among thalassemia group 
Malay 
Chinese 
Siamese 
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        Figure 6.6: Mean age among thalassemia group. 
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6.2 Comparison CIMT measurement between thalassemia group with non- 
thalassemia group 
 
 From our study, we found that the mean value of the intima- media thickness of 
the common carotid artery in non- thalassemia group is 0.32mm. The mean value of 
the intima- media thickness of the common carotid artery in thalassemia group is 
slightly thicker than non- thalassemia group measuring 0.45 mm.  
 
 An independent t-test was done to compare sonographic CIMT measurement 
between thalassemia group and non- thalassemia group. Assumptions were checked 
before performing the test. Assumptions for random sample and independent 
observation were completed during study design stage. Then, normality of both 
groups is checked by using histogram and is found to be normally distributed as in 
Figure 6.7 and figure 6.8. Assumptions for homogeneity of the variance is checked by 
using Levene’s Test and equal variance is assumed (p = 0.093). 
 
Result for independent t-test is as shown in Table 6.1. With p value <0.001 
and confidence intervals does not include 0, conclusion is made based on alternative 
hypothesis. We were 95% sure that the mean CIMT of those having Thalassemia 
(0.45) is significantly higher than those not having thalassemia (0.32) with the 
confidence interval lies between -0.17 and -0.09. 
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Figure 6.7: Mean CIMT among non- thalassemia group. 
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          Figure 6.8: Mean CIMT among thalassemia group. 
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  Table 6.1:  Mean CIMT between thalassemia and non- thalassemia group (n=80) 
Study 
subjects 
Variable mean CIMT 
(SD) 
Mean 
difference  
(95 % CI) 
t statistics p value 
Thalassemia 
group 
0.45 (0.10)  
-0.13  
(-0.17, -0.09) 
 
-6.43 
 
<0.001 
Non- 
thalassemia 
group 
0.32 (0.08) 
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6.3 Association between CIMT and patients’ age, disease duration, numbers of 
blood transfusion and serum ferritin level. 
 
From the data that have been collected, the mean value of disease duration of 
the thalassemia patient is 11.8 years with mean value of serum ferritin level is 
4447.0ng/dL and mean value of number of blood transfusion is 131.8 times (Table 
6.2).  
 
To look for any association between mean CIMT measurements of 
thalassemia patient with patient’s age, disease duration, number of blood transfusions 
and serum ferritin level, a multiple linear regression test (MLR) was performed. 
Scatter of plot of each variable against the outcome was plotted (figure 6.9, 6.10, 6.11 
and 6.12) and separate simple linear regression (SLR) was performed prior 
performing the MLR.   
 
 
Table 6.2:  Thalassemia patient mean disease duration, serum ferritin level 
and numbers of blood transfusion 
Variable Mean (SD) 
Disease duration (year) 11.8 (5.9) 
Serum ferritin level (ng/dL) 4447.0 (2642.6) 
Numbers of blood 
transfusion (times) 
131.8 (11.8) 
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Figure 6.9: Age against mean CIMT 
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Figure 6.10: Disease duration against mean CIMT 
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Figure 6.11: Number of blood transfusion against mean CIMT 
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Figure 6.12: Serum ferritin level against mean CIMT 
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From the scatter plot, all four variables showed positive relationship with the 
mean CIMT. Further analysis using simple linear regression (SLR) was done. Results 
for the separate SLR are shown in table 6.3. 
 
Table 6.3: Association between age, disease duration, numbers of blood 
transfusion and serum ferritin and mean CIMT among 
thalassemia patient (n=40) using simple linear regression test. 
Variable b* (95% CI) t statistics p value r2 
Age 0.003 (0, 0.06) 1.9 0.06 0.21 
Disease duration 0.007 (0.002, 0.012) 2.85 0.007 0.42 
Numbers of blood 
transfusion 
0.001 (0.001, 0.001) 5.59 <0.001 0.67 
Serum ferritin 7x10-6 (0.00, 0.00) 1.153 0.256 0.18 
                * crude regression coefficient 
 
 
 
For the multiple linear regression tests, variables selections into the model 
were performed using stepwise, forward and backward methods. Only variable 
number of blood transfusion is found to be significant in the model (Table 6.4).  
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   Table 6.4: Factor associated with mean CIMT among thalassemia patient 
(n=40) using multiple linear regression test. 
Variable b* (95% CI) t 
statistics 
p value r2 
Numbers of blood 
transfusion 
0.001 (0.001, 0.001) 5.59 <0.001 0.67 
                * crude regression coefficient 
 
 
This MLR test requires few assumptions to be fulfilled. Scatterplot of 
unstandardized residual versus unstandardized predicted value were plotted as in 
Figure 6.13 to check if its linearity and equal variance are met. Independent 
observation was settled during study design stage. Normality of the residual was also 
checked and is normally distributed as in Figure 6.14. Assumptions of relationship 
between residual and variable number of blood transfusion was also checked by 
plotting the scatter plot and is met as in Figure 6.15. Since all assumptions are met, 
the final model for second objective is achieved. Number of blood transfusion is the 
only variable found to have association with mean CIMT.  
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Figure 6.13 Assumption: Unstandardized residual against 
unstandardized predicted value 
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            Figure 6.14 Assumption: Normality of residual 
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           Figure 6.15  Assumption: Unstandardized residual against numbers of blood 
transfusion 
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7.0  DISCUSSION 
7.1      Overview 
Thalassemia patient lifespan nowadays has been increased significantly 
compared to previously due to the advancement of the medical treatment and better 
healthcare system. As a result, more transfusion-related complications had been seen 
among the thalassemic patients which are associated with increased in iron overload. 
One of the rising trends seen in thalassemia patient is the thromboembolism 
complication. The incidence of stroke in beta thalassemia major patients ranges from 
2% to 20% according to studies (Borgna Pignatti et al., 1998). Another study shows 
that up to 29% of beta thalassemia intermedia developed either deep vein thrombosis, 
pulmonary embolism or portal vein thrombosis during a 10-year follow up (Cappellini 
et al., 2000). 
 
There are few methods that had been advocate for the assessment of iron 
overload in thalassemia patient. These include serum ferritin, liver biopsy and liver 
MRI. Serum ferritin although is an easy and cheap investigation had been found to be 
inaccurate in assessment for iron overload. Liver biopsy is an invasive method and 
depends on technicality for correct assessment. MRI T2* imaging is non-invasive 
technique with high reproducibility for iron overload assessment. A study done in Iran 
showed there was a correlation between liver iron overload severity based on liver 
MR T2* imaging and sonographic CIMT measurement (Akhlaghpoor et al., 2010). 
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Sonographic CIMT measurement is a recognised surrogate marker for future 
cardiovascular events  (Bots et al., 1997). It is increasingly being used to assess 
cardiovascular risk as atherosclerotic disease in the carotid artery has been associated 
with both coronary and cerebrovascular disease (Craven et al., 1990).  
 
There have been few studies investigating CIMT measurement in thalassemia 
patient which show a significant increased than normal population and there are few 
factors that have been associated with the CIMT increment. Sonographic CIMT 
measurement is also recommended to be done in beta thalassemia patients as a non-
invasive early diagnostic tool (Ismail and El-Sherif, 2010; Dogan and Citak, 2011)  
and for vascular risk stratification (Tantawy et al., 2009).  
 
There is no similar study done on sonographic CIMT measurement on 
thalassemia patient in in Southeast Asia, particularly Malaysia. This study would be 
helpful because of the different type of thalassemia in Malaysia which mainly 
comprised of HbE β-thalassemia, which is a structural β-globin Hb variant with a β+ 
phenotype (George, 2013). HbE β-thalassemia shows highest frequencies in Asia such 
as India, Bangladesh, Thailand, Laos, Cambodia (Olivieri et al., 2011) and also in 
Malaysians’ Malay population (George, 2013). 
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 7.2       Demographic Characteristic 
Our study has managed to include a total of 80 subjects, which consist of 40 
thalassemia and 40 non- thalassemia subjects. Our thalassemia subjects is slightly 
more than previous studies which had been done in Italy (Cusmà Piccione et al., 
2013), Turkey (Dogan and Citak, 2011; Gursel et al., 2012), Egypt (Tantawy et al., 
2009; Ismail and El-Sherif, 2010), Greece (Hahalis et al., 2008) and Hong Kong 
(Cheung et al., 2006) which ranges from 20 to 36 subjects.  Our study managed to get 
higher subject samples than previous study possible due to we include all type of 
thalassemia and did not restrict our subjects only to beta thalassemia major like other 
studies. The sex distribution is almost equal between male and female with the mean 
age of 15.65± 6.8 years. 
 
The mean age for other studies are almost similar to our study except for 
Cusmà Piccione et al., 2013 and Hahalis et al., 2008 which involves older subjects 
(mean age of 35± 8years and 27± 7years respectively). Other studies recruit slightly 
younger subjects such as Dogan and Citak, 2011(median age of 8 years) and Ismail 
and El-Sherif, 2010 (mean age of 7.2± 3.4years). Our normal subjects (n=40) also 
almost equally distributed between male and female, with mean age of 19.13± 8.1 
years. 
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  Based on the race, our thalassemia study sample comprises 92.5% of Malays 
(n=37), 5% Chinese (n=2) and 2.5% Siamese (n=1). The majority of Malay subjects is 
likely due to the Malay race predominance in Malaysia which is followed by Chinese 
and Indian (Elizabeth and Ann, 2011).  
    
  
75 
7.3  Comparisan between thalassemia CIMT measurements and non- 
thalassemia group. 
 
According to our study, the mean thalassemia CIMT measurement was 0.45± 
0.1mm as compared to non- thalassemia group which measured 0.32± 0.08mm. From 
the data analysis, we found that thalassemic CIMT measurement was significantly 
higher than the non- thalassemia group. This was in concordance with other studies 
that had been done previously by Cheung et al., 2006 (0.45± 0.04mm vs 0.39± 
0.02mm), Hahalis et al., 2006 (0.51± 0.07mm vs 0.46± 0.07mm), Tantawy et al., 
2009 (0.73mm vs 0.63mm), Ismail and El-Sherif, 2010 (0.46± 0.08mm vs 0.35± 
0.03mm), Dogan and Citak, 2011 (0.87mm vs 0.74mm) and Gursel et al., 2012 (0.56± 
0.06mm vs 0.48± 0.05mm).  
 
The increased in the CIMT could be attributed by the hypercoagulability state 
in thalassemia. Among the causes of the hypercoagulability that have been identified 
are abnormal platelets, abnormal red blood cells, decreased in coagulation inhibitors, 
iron overload, hyperviscosity, endothelial damage, genetic mutations, cardiac and 
liver dysfunction and hormonal deficiencies (Eldor and Rachmilewitz, 2002; 
Panigrahi and Agarwal, 2007; Taher et al., 2008; Cappellini et al., 2010).  
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7.4  Correlation between thalassemia CIMT measurements and patient’s 
number of blood transfusions. 
 
Previous study had observed that there was a correlation between thalassemia 
patient’s sonographic CIMT measurements with patients’ number of blood 
transfusions. Our study also tried to show an association between the CIMT 
measurements with patient’s number of blood transfusions. 
 
From the single linear regression test, we had found that there was a 
significant linear relationship between thalassemia mean CIMT measurement and the 
number of blood transfusion (p < 0.001). It was observed that increasing in number of 
blood transfusion by 100 times will increase the mean CIMT by 1mm. On further 
analysis using multiple linear regression tests, we concluded that the numbers of 
blood transfusion was the only independent factor that significantly associated with 
patient’s CIMT measurement. Our finding was in harmony with study done by Dogan 
and Citak, 2011. The study which was done in Turkey compared 33 beta thalassemia 
major patients which include 22 boys and 11 girls with median age of 8 years old with 
30 healthy children. Another study done in Egypt by Ismail and El- Sherif in 2010 
which involved 15 beta thalassemia major patients also showed there was a significant 
difference in CIMT measurement in relation to frequency of blood transfusion.   
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This was likely related to increase in iron overload as the frequency of blood 
transfusion is increased (McLeod et al., 2009).  The finding by Cusmà Piccione et al., 
2013 which found there is no significant difference in CIMT measurement between 
general populations with non-iron overload thalassemia patient further supports our 
finding.  Iron stores plays a strong role in atherogenesis (Kiechl et al., 1997) and iron 
overload is thought to be one of the factors attributed to increased hypercoagulability 
in thalassemia patient.  
 
Iron chelating agents had been introduced to blood transfusion depended beta 
thalassemia patient to reduce the iron overload. Desferoxamine is the first iron 
chelating agent that was introduced which was given through subcutaneous or 
intravenous route and studies had shown that it has a role to reduce the cardiovascular 
complication. However the discomfort it produced during administration and the 
exuberant treatment cost had an effect to its compliancy among thalassemia patient 
(Delea et al., 2007; Dahlui et al., 2009; Viprakasit et al., 2009). As a result, new oral 
chelating agents had been introduced to increase the compliancy.    
 
The exact mechanism of iron promoting atherogenesis is still unclear (De Valk 
and Marx, 1999). According to the ‘iron hypothesis’, iron is said to be 
proatherogenetic when it is in catalytically active form (Vinchi et al., 2014). It        
participates in the formation of reactive oxygen species and induces lipid-
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peroxidation, triggering endothelial activation, smooth muscle cell proliferation and 
macrophage activation.  
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7.5   Correlation between thalassemia CIMT measurements and patient’s 
serum ferritin level. 
 
From our study, the mean serum ferritin level of the thalassemia patients’ 
measures 4470± 2642.6ng/ml. The measurement is slightly higher than previous study 
with the highest being recorded is 2860ng/ml (Dogan and Citak, 2011), followed by 
2342.7ng/ml (Tantawy et al., 2009), 2235ng/ml (Gursel et al., 2012), and 1527ng/ml 
(Cheung et al., 2006).  
 
From our regression analysis, we did not find any association between 
patients’ CIMT with their serum ferritin levels. Our finding corresponds with few 
studies (Cheung et al., 2006; Hahalis et al., 2008; Gursel et al., 2012). However, there 
were few studies done in Egypt and Turkey showing an association between patient 
CIMT with serum ferritin levels (Tantawy et al., 2009; Ismail and El-Sherif, 2010; 
Dogan and Citak, 2011).  
 
The discrepancies in the result may lie in the limitations in serum ferritin 
levels in reflecting patient’s true iron load status. Serum ferritin level represents only 
1% of the total iron pool and as an acute-phase protein it is not specific 
(Argyropoulou and Astrakas, 2007).  Serum ferritin level is affected by many factors 
such as chronic inflammation, infection process, liver disease and blood loss (Rossi et 
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al., 2000; Argyropoulou and Astrakas, 2007; Eghbali et al., 2014). Our study did not 
exclude patient with hepatitis which is not rare in patients with thalassemia. Studies 
done in Pakistan (Din et al., 2014), Egypt (Mansour et al., 2011), Iran (Mirmomen et 
al., 2006) and India (Manisha et al., 2014) showed that about 49%, 40%, 19% and 
18% of the thalassemia subjects have been inflicted with hepatitis C respectively.  
 
Our study did not exclude patient with liver enzyme derangement. Study done 
by Cheng et al., 2006 and Hahalis et al., 2008 which show similar result as our study 
also did not exclude patient with impaired liver function test in their study. However 
studies done in Egypt and Turkey which exclude patient with hepatitis showed there 
were correlation between patient CIMT measurement and serum ferritin level 
(Tantawy et al., 2009; Dogan and Citak, 2011). We believed that because of this, it 
may have an effect to the serum ferritin levels in our subjects thus affecting our study 
findings.   
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7.6  Correlation between thalassemia CIMT measurement with patient’s age 
and disease duration. 
 
Previous study has also found that there is an association between patients 
CIMT ‘measurement with patients’ age. A study in Greece which involved 35 beta 
thalassemia major patients with median age of 27± 7 years old and 35 normal control 
subjects showed that there was a positive correlation between CIMT and patients’ age 
(Hahalis et al., 2008).  Tantawy et al. in 2009 also showed a positive correlation 
between CIMT and thalassemia patient’s age. The study was performed on 30 beta 
thalassemia major patients with median age of 18.4± 6.2 years. Simliar finding was 
also noted in study done by Ismail and El-Sherif, 2010.  Apart from that, study by 
Dogan and Chitak in 2012 had shown that there is a positive correlation between beta 
thalassemia patients’ CIMT with disease duration.  
 
 
From the univariate analysis in our study, we found that there is a significant 
linear relationship between thalassemic mean CIMT and disease duration (p = 0.007). 
It is observed that increasing in 50 years of disease duration will increase the value of 
CIMT reading by 0.35mm.  However on further analyzing with multivariate test, we 
did not find any significant correlation between patients’ CIMT with the disease 
duration. We also did not find any association between patients age with patient’s 
CIMT measurement on the univariate analysis. 
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The reason behind the different finding in our study may be due to the type of 
thalassemia patients that were used as subjects. Other study only included thalassemia 
major in their study which has similar disease severity and needs regular blood 
transfusion. This is slightly differs from our study as we do not limit our subject to 
only thalassemia major. All thalassemia patients who were receiving treatment or 
follow-up in our hospital were included in the study. This would likely cause 
thalassemia minor patients as well as thalassemia intermedia patients to be included in 
our study. As a result, each patient in our study has different disease severity thus 
making their blood transfusion frequency varies.  We believe that because of this, the 
iron overload burden will also varies between patients and not correlate with the age 
and disease duration of each patient, hence the incongruent result with other studies.  
 
Apart from that, the commonest form of beta thalassemia in South-East Asia is 
Hb-E beta thalassemia (George, 2013). A study among 80 blood donors in Hospital 
Universiti Sains Malaysia also showed Hb-E beta thalassemia is the commonest form 
of thalassemia (Rosline et al., 2006). The difference in the type of thalassemia from 
other studies might contribute to the result irregularities in our study, though this still 
need to be further clarified as we did not classified our subject according to their 
phenotype. 
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8.0  SUMMARY AND CONCLUSION 
Evaluation of the carotid artery intima-media thickness with high resolution 
ultrasound is easy, although operator dependent, and is extremely useful to predict the 
risk of the cardiovascular and cerebrovascular disease. Sonographic CIMT 
measurement which is also a recognised surrogate marker for future cardiovascular 
events is highly reproducible technique for quantifying atherosclerotic burden. 
 
From our study, we have found that there is significant increased CIMT 
measurement in thalassemia patient, indicating there is a higher risk of cardiovascular 
and cerebrovascular disease event compared to non- thalassemia group. 
 
Our study also conclude that the number of blood transfusions is significantly 
associated with patient’s CIMT measurement as being rationale by increased in the 
iron overload.  
 
 
 
  
84 
9.0 LIMITATION AND RECOMMENDATIONS 
9.1 Limitations 
The author has acknowledged several significant limitations of this, which 
include: 
1. This study is operator dependent; however this single operator dependent 
has been overcome with validation study which was conducted prior to the 
validation study. Furthermore, the focus, depth and gain for all the 
ultrasound examination were standardized by employing the incorporated 
program within the ultrasound equipment. 
2. The subjects who are being recruited in this study has mixed thalassemia 
clinical phenotypes, this could have an effect to the data collected 
compared to other studies which only specified to one clinical phenotype, 
thus will likely affect the end result.  
3. The non-thalassemia group that had been recruited for this study are 
assumed to be normal based on the initial questionnaire assessment. No 
further clinical or blood parameters were done for confirmation.  However, 
this can be negligible since hypertension, hyperlipidemia and diabetes 
mellitus is rare in younger age group.  
4. Hypercoagulability in thalassemia is multifactorial. Other known 
confounding factors such as anti-thrombogenic agent (protein C, protein 
S), lipids and splenectomised status has not been included in this study.  
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5. The sample size collected in this study does is inadequate for the 2nd 
objective. This would likely affect the end result of this study. 
 
9.2  Recommendation 
The author suggests that the study to be done in bigger thalassemic 
population with proper grouping of the thalassemia subjects based on their 
phenotype for more accurate evaluation. The author also recommends that 
other co-founding factors for thalassemia hypercoagulability (protein C, 
protein S, lipids and splenectomised status) to be included if similar study 
were to be done in the future. 
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Appendix 1:     
STUDY INFORMATION 
Study title :  A study of carotid intima media thickness among thalassemia 
 patients in HUSM 
 
Name of researcher: Dr Ahmad Hadif Zaidin B Samsudin (MMC Registration Number: 
43414) 
Supervisor         : Dr Juhara Haron (MMC Registration Number: 34234)  
Co-Supervisor         : Prof Madya Dr Ariffin Nasir (MMC Registration Number: 31850) 
          : Dr Rosnah Bahar (MMC Registration Number: 22368) 
 
Introduction 
You/ your child are invited to participate in a voluntary research study involving ultrasound 
examination of your neck to measure your carotid artery wall thickness. The wall thickness 
measurement has been used as risk stratification for thrombolic event (clotting of blood 
within the vessel). Before agreeing to participate in this research study, it is important that 
you read and understand this form.  If you agree to participate, you will receive a copy of this 
form to keep for your records. 
 
The purpose of this study 
The aim of the study is to measure and compare sonographic carotid artery intima media 
thickness (CIMT) between thalassemias patient with the general population. An increased in 
carotid artery intima media thickness has been associated with increased risk of 
thromboembolic event. If you/ your child are a thalassemia patient, any association of CIMT 
with you/your child’s age, disease duration, number of blood transfusion and serum ferritin 
level will be calculated. This would allow better thalassemias patient management in the 
future.  
 
Entry qualification 
The doctor in charge of this study or a research staff has discussed the requirements for 
participation in this study with you. It is important that you are truthful with the doctors and 
staff about your health history.  
Requirements for this study are: 
For thalassemia patients : You are seeking treatment/ follow up in HUSM 
For general population  : None 
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You cannot participate in this study if: 
1. You have history of hypertension, diabetes, hypercholesterolemia or connective tissue 
or metabolic diseases. 
2. You are a smoker. 
3. You are taking anti- coagulant medication or oral contraceptive pills. 
4. You are bed ridden or have history of trauma to the carotid arteries. 
 
Study Procedures 
If you agree to participate yourself/ your child for the study, a short questionnaire will be 
given. If you qualify to participate, an ultrasound examination of both sides of your/ your 
child’s neck will be done. If you/ your child are a thalassemia patient, another short 
questionnaire will be given after the ultrasound examination asking more information on 
your/your child’s disease duration and numbers of blood transfusion. Serum ferritin level will 
be review later from the medical record.  
Ultrasound examination steps: 
You/ your child will be asked to lie still on the bed with the head in slightly hyperextended 
position. An ultrasound examination of both sides of the neck will be performed. The whole 
examination may take 10-20 minutes in duration. You/ your child will be allowed to return 
home after that. 
 
Risk: 
As ultrasound wave is a non-ionising wave, therefore there is no risk of radiation and is it 
safe. If any new information found during this study may change the agreement and to 
continue to participate, you will be notified as soon as possible. 
 
 
Reporting health expereinces. 
 
If you have any injury, bad effect, or any other unusual health experience after the ultrasound 
examination, make sure that you immediately tell the nurse or Dr. Ahmad Hadif Zaidin B 
Samsudin [MMC Registration No:43414] at 09-7673468 or 013-9814800.  You can call at 
anytime, day or night, to report such health experiences. 
 
 
Participation in this study: 
Your/ your child’s participation in this study is voluntary. You can reject or terminated your/ 
your child’s participation in this study at any time without penalty or loss of any benefit that 
would have been earned by you. 
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Possible Benefits 
The study procedures will be provided at no cost to you.  You may receive information about 
your health from any physical examination and laboratory tests to be done in this study. We 
hope that the outcome and information regarding this research will beneficial to future 
patients. 
 
Questions:                                                                                                                                           
If you have any questions about this study or your right, please contact;                                  
 
Dr Ahmad Hadif Zaidin B Samsudin (MMC: 43414),                                                                                   
Department of Radiology, HUSM                                                                                                
School of Medical Sciences, USM Health Campus                                                                    
Tel: 013-9814800 
   Email : hadif@kk.usm.my/ sam_hadif@yahoo.com 
 
 
If you have any question regarding the approval ethical, please contact:                                      
 
Mr. Mohd Bazlan Hafidz Mukrim 
Secretary of Human Research Ethics Committee USM 
Centre for Research Initiatives, Clinical & Health Sciences 
USM Health Campus 
Tel. No. : 09-767 2354 / 09-767 2362 
Email : bazlan@usm.my/Jepem@kk.usm.my 
 
Confidentiality: 
Your/ your child medical information will kept confidential by doctor and staffs and will not 
be revealed unless is required by law. Your/ your child original medical records may be 
reviewed by ethical and regulatory authorities for the purpose of verifying the procedures or 
clinical research data. The medical information may be store in a computer or processed. By 
signing this consent form, your authorised the records, information storage and transfer of 
data as describe above.  
 
Signature: 
To be entered into the study, you or a legal representative must sign and data the signature 
page 
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Patient Consent  Form 
Title of study:   A study of carotid intima media thickness among thalassemia 
patients in HUSM  
Name of researcher : Dr Ahmad Hadif Zaidin B Samsudin (MMC Reg Number : 43414) 
Supervisor                : Dr Juhara B Harun (MMC Reg Number : 34234)  
Co-Supervisor           : Prof Madya Dr Ariffin Nasir (MMC Registration Number : 31850) 
   : Dr Rosnah Bahar (MMC Registration Number: 22368) 
To participate, you or legal representative must sign this page. By signing this page, I certify 
the following: 
• I have read all the information in the Patient Information and Consent Form, including 
any information regarding the risk in this study and I have had enough time to think 
about it. 
• All my questions were answered to my satisfaction. 
• I voluntarily agree to participate in this research study, to comply with the study 
procedures and provide necessary information to doctor, nurses and other staff 
members as requested. 
• I can terminate my participation in the study at any time. 
• I have received a copy of the Patient Information and Consent Form to keep for 
myself. 
 
Patient’s Name  
     
 Patient number & initial 
 Patient Identification Card No  (new) 
 
 Patient Identification Card No(old) 
Patient’s / legal representative’s name/ IC and 
signature              
           
 Date(dd/MM/yy) 
Researcher’s  name & signature  
 
 
 Date(dd/MM/yy) 
Witness’s name & signature   Date(dd/MM/yy) 
 
Note:  i) All subject/patients who are involved in this study will not be covered by insurance. 
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Appendix 2: 
MAKLUMAT KAJIAN 
Tajuk kajian:    Kajian tentang ketebalan ‘carotid intima media’ di kalangan  
                                    pesakit thalassemia HUSM.  
Nama Pengkaji : Dr Ahmad Hadif Zaidin B Samsudin (Nombor MMC: 43414) 
Penyelia                : Dr Juhara B Harun (Nombor MMC: 34234)  
Penyelia bersama : Prof Madya Dr Ariffin Nasir (Nombor MMC: 31850) 
Penyelia bersama : Dr Rosnah Bahar (MMC Registration Number: 22368) 
 
Pengenalan  
Anda/ anak anda dipelawa untuk menyertai satu kajian penyelidikan secara sukarela yang 
melibatkan ujian pemeriksaan ultrasound kedua-dua belah leher untuk merekodkan bacaan 
ketebalan dinding salur arteri carotid anda/ anak anda. Bacaan ketebalan ini secara amnya 
dapat memberi maklumat tentang risiko penyakit sesalur darah tersumbat. Sebelum anda 
bersetuju untuk menyertai kajian penyelidikan ini, adalah penting anda membaca dan 
memahami borang ini. Sekiranya anda menyertai kajian ini, anda akan menerima satu salinan 
borang ini untuk disimpan sebagai rekod anda. 
 
Tujuan kajian 
Kajian ini bertujan untuk mengukur dan membandingkan ketebalan ‘carotid intima media’ 
(CIM) diantara pesakit thalassemia dengan populasi umum dengan menggunakan mesin 
ultrasound. Kajian terdahulu mendapati ukuran CIM yang tebal telah dikaitkan dengan risiko 
pembuluh darah tersumbat. Faktor- faktor seperti umur pesakit thalassemia, jangkamasa 
penyakit, bilangan pemindahan darah dan paras ferritin darah akan dikaji sekiranya 
mempunyai kaitan dengan ketebalan CIM. Ini supaya rawatan pesakit thalassemia dapat 
dipertingkatkan pada masa hadapan. 
 
Kelayakan penyertaan 
Doktor yang bertangungjawab dalam kalian ini atau salah seorang daripada kakitangan kajian 
akan membincangkan dengan anda tentang kelayakan anda untuk menyertai kajian ini. 
Adalah penting untuk anda berterus terang dengan doktor dan kakitangan tersebut tentang 
sejarah kesihatan anda. 
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Syarat kelayakan bagi menyertai kajian ini adalah: 
Bagi pesakit thalassemia : anda telah/ sedang mendapat rawatan di HUSM                                                                          
Bagi populasi umum       : tiada   
Anda tidak boleh menyertai kajian ini sekiranya mempunyai ciri-ciri berikut: 
1. Mempunyai masalah tekanan darah tinggi, kencing manis, paras cholesterol tinggi, 
penyakit “connective tissue” atau metabolik. 
2. Anda seorang perokok. 
3. Anda sedang mengambil ubat anti- koagulant (cair darah) atau pil perancang 
kehamilan. 
4. Anda terpaksa terlantar diatas katil pada jangkamasa yang lama. 
5. Anda pernah mengalami kecederaaan kepada salur darah arteri karotid.  
 
 
Prosedur kajian 
Jika anda bersetuju membenarkan diri anda/ anak anda untuk menyertai kajian ini, satu set 
soalan-selidik yang pendek akan diberikan. Jika anda/ anak anda layak, pemeriksaan 
ultrasound kedua-dua belah leher akan dilakukan. Jika anda penghidap penyakit thalassemia, 
anda akan diberikan satu lagi set soal-selidik yang pendek untuk mengetahui jangkamasa 
penyakit anda/ anak anda dan bilangan transfusi darah telah diambil. Maklumat mengenai 
paras ferittin darah akan diambil daripada rekod perubatan anda.  
Langkah –langkah ujian ultrasound: 
Anda/ anak anda akan dibaringkan diatas katil dan kepala akan didongakkan sedikit keatas. 
Anda/ anak anda akan diminta untuk meminimumkan pergerakan kepala sebanyak mana 
yang buleh semasa pemeriksaan ultrasound kedua- dua belah akan dilakukan. Pemeriksaan 
ini mungkin akan mengambil masa diantara 10 hingga 20 minit dan anda/ anak anda akan 
dibenarkan pulang selepas pemeriksaan tersebut 
 
Risiko 
Gelombang ultrasound adalah gelombang yang tidak beradiasi, jadi tiada risiko radiasi di 
dalam pemeriksaan ultrasound dan ia adalah selamat. Jika ada maklumat tambahan yang 
dijumpai semasa kajian ini berjalan yang boleh mengubah keputusan anda bagi menyertai 
kajian ini, anda akan diberitahu dengan kadar segera. 
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Melaporkan pengalaman kesihatan 
Jika anda mengalami apa-apa kecederaan, kesan buruk, atau apa-apa pengalaman kesihatan 
yang luarbiasa sejurus selepas kajian ini, pastikan anda memberitahu jururawat atau Dr. 
Ahmad Hadif Zaidin B Samsudin [No. Pendaftaran Penuh Majlis Perubatan Malaysia:43414] 
di talian 09-7673468 atau 013-9814800 secepat mungkin. Anda boleh membuat panggilan 
pada bila-bila masa, siang atau malam, untuk melaporkan pengalaman sedemikian. 
 
Penyertaan dalam kajian 
Penyertaan anda dalam kajian ini adalah secara sukarela. Anda berhak menolak untuk 
menyertai kajian ini atau anda boleh menamatkan penyertaan anda pada bila-bila masa, tanpa 
sebarang hukuman atau kehilangan manfaat yang sepatutnya anda perolehi. 
Penyertaan anda juga mungkin boleh diberhentikan oleh doktor yang terlibat dalam kajian ini 
tanpa persetujuan anda. Sekiranya anda berhenti menyertai kajian ini, doktor yang terlibat di 
dalam kajian ini atau salah seorang kakitangan akan berbincang dengan anda mengenai apa-
apa isu perubatan berkenaan dengan pemberhentian penyertaan anda. 
 
Manfaat yang mungkin 
Prosedur kajian ini akan diberikan kepada anda tanpa kos. Anda mungkin menerima 
maklumat tentang kesihatan anda daripada pemeriksaan ultrasound dan ujian makmal yang 
dilakukan dalam kajian ini. Hasil atau maklumat kajian ini diharapkan, dapat memberi 
manfaat kepada pesakit-pesakit pada masa hadapan. Anda tidak akan menerima sebarang 
pampasan kerana menyertai kajian ini. Namun sebarang keperluan perjalanan berkaitan 
dengan penyertaan ini akan diberi. 
 
Persoalan 
Sekiranya anda mempunyai persoalan mengenai kajian ini atau berkenaan hak-hak anda, sila 
hubungi: 
Dr Ahmad Hadif Zaidin b Samsudin (No MMC: 43414) 
Jabatan Radiologi, HUSM 
Pusat Pengajian Sains Perubatan 
USM Kampus Kesihatan 
16150 Kubang Kerian. 
Tel 013-9814800. 
Email: hadif@kk.usm.my/ sam_hadif@yahoo.com 
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Sekiranya anad mempunyai sebarang soalan berkaitan kelulusan etika kajian ini, sila 
hubungi: 
En. Mohd Bazlan Hafidz Mukrim 
Setiausaha Jawatankuasa Etika Penyelidikan (Manusia) USM 
Pusat Inisiatif Penyelidikan -Sains Klinikal & Kesihatan 
USM Kampus Kesihatan. 
No. Tel: 09-767 2354 / 09-767 2362 
Email : bazlan@usm.my/Jepem@kk.usm.my 
 
 
Kerahsiaan  
Maklumat perubatan anda akan dirahsiakan oleh doktor dan kakitangan kajian. Ianya tidak 
akan dedahkan secara umum melainkan jika ia dikehendaki oleh undang-undang. 
 
Data yang diperolehi dari kajian yang tidak mengenalpasti anda secara perseorangan 
mungkin akan diterbitkan untuk tujuan memberi pengetahuan baru. 
Rekod perubatan anda yang asal mungkin akan dilihat oleh pihak penyelidik, Lembaga Etika 
kajian ini dan pihak berkuasa regulatori untuk tujuan mengesahkan prosedur dan/atau data 
kajian klinikal.  Maklumat perubatan anda mungkin akan disimpan dalam komputer dan 
diproses dengannya. 
Dengan menandatangani borang persetujuan ini, anda membenarkan penelitian rekod, 
penyimpanan maklumat dan pemindahan data seperti yang dihuraikan di atas. 
 
Tandatangan 
Untuk dimasukkan ke dalam kajian ini, anda atau wakil sah anda mesti menandatangani serta 
mencatatkan tarikh halaman tandatangan.  
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Borang Keizinan Pesakit 
(Halaman Tandatangan) 
 
Tajuk Kajian:  Kajian tentang ketebalan ‘carotid intima media’ di kalangan 
             pesakit thalassemia HUSM.  
Nama Pengkaji : Dr Ahmad Hadif Zaidin B Samsudin (Nombor MMC: 43414) 
Penyelia                : Dr Juhara B Harun (Nombor MMC: 34234)  
Penyelia bersama : Prof Madya Dr Ariffin Nasir (Nombor MMC: 31850) 
   : Dr Rosnah Bahar (MMC Registration Number: 22368) 
Untuk menyertai kajian ini, anda atau wakil sah anda mesti menandatangani mukasurat ini. Dengan 
menandatangani mukasurat ini, saya mengesahkan yang berikut: 
 
  Sa ya te lah  m em baca sem ua m ak lum at  da lam  Borang Mak lumat  dan  
Ke iz inan Pesak i t  i n i  t e rm asuk  apa-apa m ak lum at  berka i tan  r is iko  yang  
ada da lam  ka j ian  dan saya  te lah  pun  d iber i  m asa yang m encukup i  
un tuk  m em per t im bangkan m ak lum at  te rsebu t .  
  Sem ua soa lan-soa lan  saya te lah  d i j awab dengan m em uaskan.  
  Sa ya,  secara  sukare la ,  berse tu ju  m enyer ta i  ka j ian  pen ye l id ikan in i ,  
m em atuh i  sega la  p rosedur  ka j ian  dan m em ber i  m ak lum at yang  
d iper lukan kepada dok tor ,  para  ju rurawa t  dan  juga kak i tangan la in  
yang berka i tan  apab i la  d im in ta .  
  Sa ya bo leh  m enam atkan penyer taan sa ya  da lam  ka j ian  in i  pada b i l a -
b i l a  m asa.  
  Sa ya te lah  pun m ener im a sa tu  sa l inan Borang Mak lum at  dan Ke iz inan  
Pesak i t  un tuk  s im panan per ibad i  saya .  
 
 
 
Nama Pesakit (Dicetak atau Ditaip)    Nama Singkatan & No. Pesakit 
 
 
 
No. Kad Pengenalan Pesakit (Baru)    No. K/P (Lama) 
 
 
 
 
Tandatangan Pesakit atau Wakil Sah    Tarikh (dd/MM/yy)    
         
 
 
 
Nama & Tandatangan  Individu yang Mengendalikan    Tarikh (dd/MM/yy) 
Perbincangan Keizinan (Dicetak atau Ditaip) 
 
 
 
Nama Saksi dan Tandatangan     Tarikh (dd/MM/yy) 
 
Nota: i) Semua subjek/pesakit yang mengambil bahagian dalam projek penyelidikan ini tidak dilindungi insuran. 
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Appendix 3 
Borang kaji-selidik subjek A (Questionnaire A) 
No pendafaran:___________________ 
 
Sila jawab soalan dibawah dengan sejujur yang buleh. Segala maklumat yang diberikan 
adalah rahsia dan hanya akan digunakan untk tujuan penyelidikan sahaja. 
 
1. Adakah anda/ anak anda mengidap penyakit seperti dibawah:   
 Darah tinggi  Ya Tidak 
 Kencing Manis  Ya Tidak 
 Hypercholesterolemia/ Tinggi cholesterol Ya Tidak 
 Obesiti/ berat berlebihan Ya Tidak 
 Penyakit kronik (penyakit metabolik, penyakit “connective 
tissue”) 
Ya Tidak 
 
2. Adakah anda/ anak anda menghisap rokok atau sedang 
mengambil ubat anti- koagulant (cair darah) atau pil 
perancang kehamilan 
Ya Tidak 
 
3 Pernakah sebelum ini anda/ anak anda ditimpa sakit yang 
teruk sehingga tidak dapat bangun dan terpaksa terlantar 
diatas katil pada jangkamasa yang lama. 
Ya Tidak 
 
4 Pernakah sebelum ini anda/anak anda mengalami 
kecederaaan kepada salur darah arteri carotid (leher). 
Ya Tidak 
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Appendix 4 
 
Borang kaji-selidik subjek B (Questionnaire B) 
No pendafaran:___________________ 
 
1. Berapakah umur anda/ anak anda       …………..tahun 
 
2. Adakah anda/ anak anda mengidap penyakit thalassemia 
- Jika ya, sila teruskan menjawab soalan seterusnya 
Ya Tidak 
 
3. Sejak umur berapa tahun anda/ anak anda mengidap penyakit 
thalassemia? 
…………..tahun 
 
4. Sudah berapa kali anda/ anak anda telah menerima transfusi 
darah 
…………..kali 
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Data collection sheet 
 
General population 
Registered 
number (RN) 
CIMT 1st reading CIMT 2nd reading CIMT 3rd reading CIMT mean 
1. Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
2. Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
3. Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
4. Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
5. Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
6. Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
7. Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
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Data collection sheet 
 
Thalassemia subjects 
 
 
Registered 
number (RN) 
CIMT 1st reading CIMT 2nd reading CIMT 3rd reading CIMT mean 
 Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
Right=…...mm 
Left=…….mm 
………..mm 
 
 
Age    : _____________ year 
Disease duration  : _____________ year 
Number of blood transfusion : _____________ times 
Serum ferittin level  : _____________ mg/dL 
 
